Treatment of amyotrophic lateral sclerosis - What is the next step?

Journal of Neurology, Supplement

Volumn 247, Issue 6, 2000, Pages 13-18

  Ludolph, A C ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Amyotrophic lateral sclerosis; Neurodegeneration; Riluzole

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; CREATINE; GLUTAMATE RECEPTOR ANTAGONIST; METAL CHELATE; NEUROPROTECTIVE AGENT; RILUZOLE; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PHARMACOLOGICAL PROCEDURES; PRIORITY JOURNAL; TRANSGENIC ANIMAL; ANIMAL; DISEASE MODEL; FEDERATED STATES OF MICRONESIA; GENETICS; INDONESIA; MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BIOMARKERS; DISEASE MODELS, ANIMAL; HUMANS; INDONESIA; MICE; MICRONESIA; NEUROPROTECTIVE AGENTS; SUPEROXIDE DISMUTASE;

EID: 0034523307     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03161074     Document Type: Conference Paper

References (55)

1. Partial deficiency of manganese superoxid dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis
2. Monitoring disease progression in presymptomatic and early Huntington's disease: D1 and D2 ligand PET and the unified Huntington's rating scale
3. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis
4. 11C) Raclopride PET studies of the Huntington's disease rate of progression: Relevance of the trinucleotide repeat length
5. Progressive motor neuron impairment in an animal model of familial amyotrophic lateral sclerosis
6. Energetics in the pathogenesis of neurodegenerative diseases
7. A controlled trial of riluzole in amyotrophic lateral sclerosis
8. Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease. Sub-group analysis and follow-up measurements
9. Elevated "hydroxyl radical" generation in vivo in an animal model of amyotrophic lateral sclerosis
10. ALS-linked SOD 1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
11. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild type SOD1
12. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis
13. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis
14. Equine motor neuron disease: A preliminary report
15. Collateral nerve sprouting and twitch forces of single motor units in conditions with partial denervation in man
16. The pharmacology and mechanism of action of riluzole
17. Carboxyfullerenes as neuroprotective agents
18. C-pk11195 positron emission tomography (PET): An in vivo indicator for activated microglia in multiple sclerosis lesions
19. Increased 3-nitrotyrosine and oxidative damage in mice with a human Cu,Zn superoxide dismutase mutation
20. Inhibition of ICE slows ALS in mice
21. C) Pk 11195 and positron emission tomography after ischemic stroke
22. C) Pk 11195 microglia imaging ion patients suffering from multisystem atrophy
23. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation
24. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
25. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis
26. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS
27. Cortical motor-sensory hypometabolism in amyotrophic lateral sclerosis: A PET study
28. The copper chelator d-penicillamine delays on-set of disease and extends survival in a transgenic mouse model of amyotrophic lateral sclerosis
29. Motor neuron degeneration induced by excitotoxin agonists has features in common with those seen in the SOD-1 transgenic mouse model of amyotrophic lateral sclerosis
30. Neuroprotective effects of creatine in a transgenic animal model of ALS
31. Calcineurin and calbindin immunoreactivity in the spinal cord of G93A superoxide dismutase transgenic mice
32. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1
33. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis
34. Dose-ranging study of riluzole in amyotrophic lateral sclerosis
35. Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model
36. Enhanced oxygen radical production in a transgenic mouse model of familial amyotrophic lateral sclerosis
37. Decline of ALS in the Irian Jaya disease epicenter
38. Problems and pitfalls in the diagnosis of ALS
39. The role of excitotoxicity in ALS: Which is the evidence?
40. Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease
41. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis
42. An (18F) Dopa PET and clinical study of the rate of progression in Parkinson's disease
43. 18F) Dopa PET findings in early Parkinson's disease
44. Benefit of a combined treatment with trienetine and ascorbate in familial amyotrophic lateral sclerosis model mice
45. 1H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla
46. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury
47. Inhibition of energy metabolism by 3-nitropropionic acid activates ATP-sensitive potassium channels
48. Failure of neuronal ion exchange, not potentiated excitation causes excitotoxicity after inhibition of oxidative phosphorylation
49. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole
50. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
51. Experimental therapeutics for neurodegenerative disorders: Unmet needs
52. Lathyrism and western Pacific amyotrophic lateral sclerosis: Etiology of short and long, latency motor-system disorders
53. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria